Skip to main content

Welcome to Janssen Europe, Middle-East and Africa

VISIT JANSSEN GLOBAL

As always, Janssen remains committed to healthcare professionals and patients, as well as to our employees and communities

As always, Janssen remains committed to healthcare professionals and patients, as well as to our employees and communities

COVID-19 Coronavirus Infections

Title

COVID-19

What is Janssen doing to fight this pandemic?

1. Accelerating
the development for a vaccine
for COVID-19

2. Screen a library
of antiviral molecules
in collaboration with partners.
To help identify
potential
treatments for the virus.

3. Collaborate with regulators,
healthcare organisations,
institutions and communities
worldwide to help ensure
our research platforms, existing science and outbreak expertise
can be maximized
to stem this
public health threat.

4. Janssen made $50 million available
to support the efforts of frontline health workers.
This support will be divided over the communities
who were hit the hardest in Africa,
Europe and the Middle East.
Glad to do our part to #backthefrontline.

5. Ensure access to medicines, products, devices and solutions our patients and providers rely on.

What impact does COVID-19 have on us as a company?

With the Johnson & Johnson family,
we’ve worked out a robust business continuity plan
to keep our business going as much as usual.

We highly value our employees,
their health, and
the health of their families.
Find out how we commit
to keeping our colleagues safe.

The latest updates

Biopharma Leaders Unite To Stand With Science

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate

Follow all latest updates via LinkedIn and Twitter